Dysregulation of the MIRLET7/HMGA2 axis with methylation of the CDKN2A promoter in myeloproliferative neoplasms

British Journal of Haematology

Volumn 168, Issue 3, 2015, Pages 338-349

  Harada Shirado, Kayo ^a   Ikeda, Kazuhiko ^a   Ogawa, Kazuei ^a   Ohkawara, Hiroshi ^a   Kimura, Hideo ^b   Kai, Tatsuyuki ^b   Noji, Hideyoshi ^a   Morishita, Soji ^c   Komatsu, Norio ^c   Takeishi, Yasuchika ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b Department of Hematology   (Japan)

^c JUNTENDO UNIVERSITY   (Japan)

Author keywords

HMGA2; Essential thrombocythaemia; Micro RNA; Polycythaemia vera; Primary myelofibrosis

Indexed keywords

CD34 ANTIGEN; HIGH MOBILITY GROUP A2 PROTEIN; LACTATE DEHYDROGENASE; MESSENGER RNA; PANOBINOSTAT; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; HYDROXAMIC ACID; INDOLE DERIVATIVE; MICRORNA; RNA;

3' UNTRANSLATED REGION; AGED; ARTICLE; CDKN2A GENE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA METHYLATION; DRUG EFFECT; FEMALE; GENE; GENE EXPRESSION; GENETIC REGULATION; GENETIC VARIABILITY; GRANULOCYTE; HMGA2 GENE; HUMAN; HUMAN CELL; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIRLET7 GENE; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; PROMOTER REGION; SPLENOMEGALY; THROMBOCYTHEMIA; U937 CELL LINE; BIOSYNTHESIS; CASE CONTROL STUDY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; TUMOR CELL CULTURE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGA2 PROTEIN; HUMANS; HYDROXAMIC ACIDS; INDOLES; MALE; MICRORNAS; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; RNA, NEOPLASM; TUMOR CELLS, CULTURED;

EID: 84921418510     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13129     Document Type: Article

References (51)

1. Abdel-Wahab, O., Manshouri, T., Patel, J., Harris, K., Yao, J.J., Hedvat, C., Heguy, A., Bueso-Ramos, C., Kantarjian, H., Levine, R.L. & Verstovsek, S. (2010) Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Research, 70, 447-452.
2. Akada, H., Akada, S., Gajra, A., Bair, A., Graziano, S., Hutchison, R.E. & Mohi, G. (2012) Efficacy of vorinostat in a murine model of polycythemia vera. Blood, 119, 3779-3789.
3. Andrieux, J., Demory, J.-L., Dupriez, B., Quief, S., Plantier, I., Roumier, C., Bauters, F., Laï, J.L. & Kerckaert, J.-P. (2004) Dysregulation and overexpression of HMGA2 in myelofibrosis with myeloid metaplasia. Genes, Chromosomes & Cancer, 39, 82-87.
4. Baxter, E.J., Scott, L.M., Campbell, P.J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G.S., Bench, A.J., Boyd, E.M., Curtin, N., Scott, M.A., Erber, W.N. & Green, A.R. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365, 1054-1061.
5. Beer, P.A., Campbell, P.J., Scott, L.M., Bench, A.J., Erber, W.N., Bareford, D., Wilkins, B.S., Reilly, J.T., Hasselbalch, H.C., Bowman, R., Wheatley, K., Buck, G., Harrison, C.N. & Green, A.R. (2008) MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood, 112, 141-149.
6. Bruchova, H., Merkerova, M. & Prchal, J.T. (2008) Aberrant expression of microRNA in polycythemia vera. Haematologica, 93, 1009-1016.
7. Chen, Z. & Riggs, A.D. (2011) DNA methylation and demethylation in mammals. The Journal of Biological Chemistry, 286, 18347-18353.
8. Christiansen, D.H., Andersen, M.K. & Pedersen-Bjergaard, J. (2003) Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia, 17, 1813-1819.
9. Copley, M.R., Babovic, S., Benz, C., Knapp, D.J.H.F., Beer, P.A., Kent, D.G., Wohrer, S., Treloar, D.Q., Day, C., Rowe, K., Mader, H., Kuchenbauer, F., Humphries, R.K. & Eaves, C.J. (2013) The Lin28b-let-7-Hmga2 axis determines the higher self-renewal potential of fetal haematopoietic stem cells. Nature Cell Biology, 15, 916-925.
10. DeAngelo, D.J., Mesa, R.A., Fiskus, W., Tefferi, A., Paley, C., Wadleigh, M., Ritchie, E.K., Snyder, D.S., Begna, K., Ganguly, S., Ondovik, M.S., Rine, J. & Bhalla, K.N. (2013a) Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis. British Journal of Haematology, 162, 326-335.
11. DeAngelo, D.J., Spencer, A., Bhalla, K.N., Prince, H.M., Fischer, T., Kindler, T., Giles, F.J., Scott, J.W., Parker, K., Liu, a., Woo, M., Atadja, P., Mishra, K.K. & Ottmann, O.G. (2013b) Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia, 27, 1628-1636.
12. Edahiro, Y., Morishita, S., Takahashi, K., Hironaka, Y., Yahata, Y., Sunami, Y., Shirane, S., Tsutsui, M., Noguchi, M., Koike, M., Imai, K., Kirito, K., Noda, N., Sekiguchi, Y., Tsuneda, S., Ohsaka, A., Araki, M. & Komatsu, N. (2014) JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan. International Journal of Hematology, 99, 625-634.
13. Fazio, P.Di., Montalbano, R. & Neureiter, D. (2012) Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines. Experimental Cell Research, 318, 1832-1843.
14. Ferguson, M. (2003) Histone deacetylase inhibition is associated with transcriptional repression of the Hmga2 gene. Nucleic Acids Research, 31, 3123-3133.
15. Fiskus, W., Pranpat, M., Balasis, M., Herger, B., Rao, R., Chinnaiyan, A., Atadja, P. & Bhalla, K. (2006) Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Molecular Cancer Therapeutics, 5, 3096-3104.
16. Fiskus, W., Buckley, K., Rao, R., Mandawat, A., Yang, Y., Joshi, R., Wang, Y., Balusu, R., Chen, J., Koul, S., Joshi, A., Upadhyay, S., Atadja, P. & Bhalla, K.N. (2009) Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells. Cancer Biology & Therapy, 8, 939-950.
17. Fusco, A. & Fedele, M. (2007) Roles of HMGA proteins in cancer. Nature Reviews. Cancer, 7, 899-910.
18. Guglielmelli, P., Zini, R., Bogani, C., Salati, S., Pancrazzi, A., Bianchi, E., Mannelli, F., Ferrari, S., Le Bousse-Kerdilès, M.-C., Bosi, A., Barosi, G., Migliaccio, A.R., Manfredini, R. & Vannucchi, A.M. (2007) Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1). Stem Cells, 25, 165-173.
19. Harrison, C., Kiladjian, J. & Al-Ali, H. (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. The New England Journal of Medicine, 366, 787-798.
20. Huang, Z.L., Failla, M.L. & Reeves, P.G. (2001) Differentiation of human U937 promonocytic cells is impaired by moderate copper deficiency. Experimental Biology and Medicine, 226, 222-228.
21. Ikeda, K., Shichishima, T., Yasukawa, M., Nakamura-Shichishima, A., Noji, H., Akutsu, K., Osumi, K. & Maruyama, Y. (2007) The role of Wilms' tumor gene peptide-specific cytotoxic T lymphocytes in immunologic selection of a paroxysmal nocturnal hemoglobinuria clone. Experimental Hematology, 35, 618-626.
22. Ikeda, K., Mason, P.J. & Bessler, M. (2011) 3′UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice. Blood, 117, 5860-5869.
23. James, C., Ugo, V., Le Couédic, J.-P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, J.L., Constantinescu, S.N., Casadevall, N. & Vainchenker, W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434, 1144-1148.
24. Jost, E., do O, N., Dahl, E., Maintz, C.E., Jousten, P., Habets, L., Wilop, S., Herman, J.G., Osieka, R. & Galm, O. (2007) Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders. Leukemia, 21, 505-510.
25. Klampfl, T., Gisslinger, H., Harutyunyan, A.S., Nivarthi, H., Rumi, E., Milosevic, J.D., Them, N.C.C., Berg, T., Gisslinger, B., Pietra, D., Chen, D., Vladimer, G.I., Bagienski, K., Milanesi, C., Casetti, I.C., Sant'Antonio, E., Ferretti, V., Elena, C., Schischlik, F., Cleary, C., Six, M., Schalling, M., Schönegger, A., Bock, C., Malcovati, L., Pascutto, C., Superti-Furga, G., Cazzola, M. & Kralovics, R. (2013) Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms. New England Journal of Medicine, 369, 2379-2390.
26. Kralovics, R., Passamonti, F., Buser, A.S., Teo, S., Tiedt, R., Passweg, J.R., Tichelli, A., Cazzola, M. & Skoda, R.C. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. The New England Journal of Medicine, 352, 1779-1790.
27. Lee, Y.S. & Dutta, A. (2007) The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes & Development, 21, 1025-1030.
28. Lee, S., Jung, J.-W., Park, S.-B., Roh, K., Lee, S.Y., Kim, J.H., Kang, S.-K. & Kang, K.-S. (2011) Histone deacetylase regulates high mobility group A2-targeting microRNAs in human cord blood-derived multipotent stem cell aging. Cellular and Molecular Life Sciences, 68, 325-336.
29. Levine, R.L. & Gilliland, D.G. (2008) Myeloproliferative disorders. Blood, 112, 2190-2198.
30. Levine, R.L., Wadleigh, M., Cools, J., Ebert, B.L., Wernig, G., Huntly, B.J.P., Boggon, T.J., Wlodarska, I., Clark, J.J., Moore, S., Adelsperger, J., Koo, S., Lee, J.C., Gabriel, S., Mercher, T., D'Andrea, A., Fröhling, S., Döhner, K., Marynen, P., Vandenberghe, P., Mesa, R.A., Tefferi, A., Griffin, J.D., Eck, M.J., Sellers, W.R., Meyerson, M., Golub, T.R., Lee, S.J. & Gilliland, D.G. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 7, 387-397.
31. Li, J., Spensberger, D., Ahn, J.S., Anand, S., Beer, P.A., Ghevaert, C., Chen, E., Forrai, A., Scott, L.M., Ferreira, R., Campbell, P.J., Watson, S.P., Liu, P., Erber, W.N., Huntly, B.J.P., Ottersbach, K. & Green, A.R. (2010) JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood, 116, 1528-1538.
32. Mascarenhas, J., Lu, M., Li, T., Petersen, B., Hochman, T., Najfeld, V., Goldberg, J.D. & Hoffman, R. (2013) A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF). British Journal of Haematology, 161, 68-75.
33. Mayr, C., Hemann, M.T. & Bartel, D.P. (2007) Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science, 315, 1576-1579.
34. Mullally, A., Lane, S.W., Ball, B., Megerdichian, C., Okabe, R., Al-Shahrour, F., Paktinat, M., Haydu, J.E., Housman, E., Lord, A.M., Wernig, G., Kharas, M.G., Mercher, T., Kutok, J.L., Gilliland, D.G. & Ebert, B.L. (2010) Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell, 17, 584-596.
35. Murakami, Y., Inoue, N., Shichishima, T., Ohta, R., Noji, H., Maeda, Y., Nishimura, J.-I., Kanakura, Y. & Kinoshita, T. (2012) Deregulated expression of HMGA2 is implicated in clonal expansion of PIGA deficient cells in paroxysmal nocturnal haemoglobinuria. British Journal of Haematology, 156, 383-387.
36. Muto, T., Sashida, G., Oshima, M., Wendt, G.R., Mochizuki-Kashio, M., Nagata, Y., Sanada, M., Miyagi, S., Saraya, A., Kamio, A., Nagae, G., Nakaseko, C., Yokote, K., Shimoda, K., Koseki, H., Suzuki, Y., Sugano, S., Aburatani, H., Ogawa, S. & Iwama, A. (2013) Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. The Journal of Experimental Medicine, 210, 2627-2639.
37. Nangalia, J., Massie, C.E., Baxter, E.J., Nice, F.L., Gundem, G., Wedge, D.C., Avezov, E., Li, J., Kollmann, K., Kent, D.G., Aziz, A., Godfrey, A.L., Hinton, J., Martincorena, I., Van Loo, P., Jones, A.V., Guglielmelli, P., Tarpey, P., Harding, H.P., Fitzpatrick, J.D., Goudie, C.T., Ortmann, C.A., Loughran, S.J., Raine, K., Jones, D.R., Butler, A.P., Teague, J.W., O'Meara, S., McLaren, S., Bianchi, M., Silber, Y., Dimitropoulou, D., Bloxham, D., Mudie, L., Maddison, M., Robinson, B., Keohane, C., Maclean, C., Hill, K., Orchard, K., Tauro, S., Du, M.-Q., Greaves, M., Bowen, D., Huntly, B.J.P., Harrison, C.N., Cross, N.C.P., Ron, D., Vannucchi, A.M., Papaemmanuil, E., Campbell, P.J. & Green, A.R. (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. New England Journal of Medicine, 369, 2391-2405.
38. Nishino, J., Kim, I., Chada, K. & Morrison, S.J. (2008) Hmga2 promotes neural stem cell self-renewal in young but not old mice by reducing p16Ink4a and p19Arf Expression. Cell, 135, 227-239.
39. Nishino, J., Kim, S., Zhu, Y., Zhu, H. & Morrison, S.J. (2013) A network of heterochronic genes including Imp1 regulates temporal changes in stem cell properties. Elife, 2, e00924.
40. Odero, M.D., Grand, F.H., Iqbal, S., Ross, F., Roman, J.P., Vizmanos, J.L., Andrieux, J., Laï, J.L., Calasanz, M.J. & Cross, N.C.P. (2005) Disruption and aberrant expression of HMGA2 as a consequence of diverse chromosomal translocations in myeloid malignancies. Leukemia, 19, 245-252.
41. Oguro, H., Yuan, J., Tanaka, S., Miyagi, S., Mochizuki-Kashio, M., Ichikawa, H., Yamazaki, S., Koseki, H., Nakauchi, H. & Iwama, A. (2012) Lethal myelofibrosis induced by Bmi1-deficient hematopoietic cells unveils a tumor suppressor function of the polycomb group genes. The Journal of Experimental Medicine, 209, 445-454.
42. Rambaldi, A., Dellacasa, C.M., Finazzi, G., Carobbio, A., Ferrari, M.L., Guglielmelli, P., Gattoni, E., Salmoiraghi, S., Finazzi, M.C., Di Tollo, S., D'Urzo, C., Vannucchi, A.M., Barosi, G. & Barbui, T. (2010) A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. British Journal of Haematology, 150, 446-455.
43. Sgarra, R., Rustighi, A., Tessari, M.A., Di Bernardo, J., Altamura, S., Fusco, A., Manfioletti, G. & Giancotti, V. (2004) Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer. FEBS Letters, 574, 1-8.
44. Shih, A.H., Abdel-Wahab, O., Patel, J.P. & Levine, R.L. (2012) The role of mutations in epigenetic regulators in myeloid malignancies. Nature Reviews. Cancer, 12, 599-612.
45. Sun, M., Song, C.-X., Huang, H., Frankenberger, C.A., Sankarasharma, D., Gomes, S., Chen, P., Chen, J., Chada, K.K., He, C. & Rosner, M.R. (2013) HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis. Proceedings of the National Academy of Sciences of the United States of America, 110, 1-6.
46. Tefferi, A. (2012) JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood, 119, 2721-2730.
47. Vardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., Harris, N.L., Le Beau, M.M., Hellström-Lindberg, E., Tefferi, A. & Bloomfield, C.D. (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 114, 937-951.
48. Wang, Y., Fiskus, W., Chong, D.G., Buckley, K.M., Natarajan, K., Rao, R., Joshi, A., Balusu, R., Koul, S., Chen, J., Savoie, A., Ustun, C., Jillella, A.P., Atadja, P., Levine, R.L. & Bhalla, K.N. (2009) Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood, 114, 5024-5033.
49. Young, A.R.J. & Narita, M. (2007) Oncogenic HMGA2: short or small? Genes & Development, 21, 1005-1009.
50. Zhan, H., Cardozo, C. & Raza, A. (2013) MicroRNAs in myeloproliferative neoplasms. British Journal of Haematology, 161, 471-483.
51. Zong, Y., Huang, J., Sankarasharma, D., Morikawa, T., Fukayama, M., Epstein, J.I., Chada, K.K. & Witte, O.N. (2012) Stromal epigenetic dysregulation is sufficient to initiate mouse prostate cancer via paracrine Wnt signaling. Proceedings of the National Academy of Sciences of the United States of America, 109, E3395-E3404.